التفاصيل البيبلوغرافية
العنوان: |
Losartan prevents methotrexate-induced liver and lung injury in rats via targeting PPAR-γ/TGF-β1/SMAD3 and Nrf2/redox signaling. |
المؤلفون: |
Abbas, Noha A. T., El-Sayed, Shaimaa S., El-Fatah, Samaa Salah Abd, Sarhan, Walaa M., Sarhan, Omnia, Abdelghany, Eman M. A., Mahmoud, Shireen S. |
المصدر: |
Zagazig University Medical Journal; Jan2023, Vol. 29 Issue 1, p135-148, 14p |
مصطلحات موضوعية: |
LOSARTAN, METHOTREXATE, LUNG injuries, OXIDATIVE stress, MALONDIALDEHYDE |
مستخلص: |
Background: Despite high efficacy-to-toxicity ratio of chemotherapeutic agent, methotrexate, toxicity remains a major concern that limits its use. Inflammatory, oxidative stress and fibrotic pathways are implicated in methotrexate-induced injury. This study aims to investigate the ability of losartan to limit methotrexate-induced liver and lung injury and to elucidate the possible underlying mechanisms. Methods: Liver and lung injury was induced in adult male Wistar rats via methotrexate ip injection twice weekly for 4weeks (0.5mg/kg), animals were divided into group1 (control) where rats received saline ip twice weekly with daily vehicles for 4weeks; group 2 to 4 included rats treated with methotrexate and began to receive drugs or vehicles concurrently, where in group2 rats received vehicles daily, whereas in group3 rats received losartan at 10mg/kg/day by gavage and those of group4 received both losartan and bisphenol-A-diglycidyl ether (BADGE, 30mg/kg). Circulating liver enzymes, histological examination of liver and lung as well as peroxisome proliferator-activated receptor-γ (PPAR-γ)/transforming growth factor-β (TGF-β)/SMAD3 and nuclear factor (erythroid-derived2)-like2 (Nrf2)/antioxidants pathways were investigated. Results: Losartan ameliorated methotrexate-induced hepatic and pulmonary injury manifested by improved circulating liver enzymes, restoration of normal liver and lung histology, upregulated PPAR-γ, suppressed TGF-β/SMAD3 signaling while activated Nrf2-mediated antioxidant defenses and reduced lipid peroxidation biomarker malondialdehyde. Losartan effects were abrogated on concurrent use of BADGE, a selective PPAR-γ antagonist. Conclusions: Losartan's antifibrotic effect via suppression of TGF-β/SMAD3 profibrotic signaling and antioxidant potentials through activation of Nrf2/antioxidant pathway are more likely attributed to PPAR-γ induction. This suggests the usefulness of losartan in limiting methotrexateassociated multiorgan injury. [ABSTRACT FROM AUTHOR] |
|
Copyright of Zagazig University Medical Journal is the property of Association of Arab Universities and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
قاعدة البيانات: |
Complementary Index |